JPMorgan Chase & Co. has notified the AMF that it indirectly crossed below the 5% threshold of Abivax voting rights on April 7. This move follows an off-market sale of Abivax shares and a reduction in shares held through financial instruments.

The U.S. banking group specified that, through its controlled subsidiaries, it holds 3,990,154 Abivax shares representing an equal number of voting rights, equivalent to 5.04% of the capital and 4.89% of the voting rights of the biotechnology company.